DDW 2017. Mo1652. IMPACT OF PROINFLAMMATORY CYTOKINES AND MESALAMINE ON THE EXPRESSION OF THE TIGHT…
jwood@krftwrk.caMay 29, 2017
DDW 2017. 263. INTESTINAL, NON-INTESTINAL, AND EXTRA-DIGESTIVE RESPONSE TO LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL…
jwood@krftwrk.caMay 29, 2017
DDW 2017. Tu1612. IRRITABLE BOWEL SYNDROME PATIENT EXPERIENCE IN CANADA Results: Respondents from every province…
jwood@krftwrk.caMay 29, 2017
DDW 2017. 971: AGE OF HELICOBACTER PYLORI ERADICATION AND SUBSEQUENT RISK OF GASTRIC CANCER DEVELOPMENT:…
jwood@krftwrk.caMay 29, 2017
DDW 2017. 616. LONG-TERM SAFETY OF ADALIMUMAB IN PATIENTS WITH CROHN'S DISEASE: FINAL DATA FROM…
jwood@krftwrk.caMay 29, 2017
On January 13th, 2017 CARE™ faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology…
jwood@krftwrk.caJanuary 23, 2017
UEGW 2016. P0402. Use of Lifestyle Interventions to Treat Bowel and/or Abdominal Symptoms Among Patients…
jwood@krftwrk.caNovember 18, 2016
ACG 2016. P346. Improvements Over Time in Individual Diarrhea-Predominant Irritable Bowel Syndrome Symptoms (IBS-D) with…
jwood@krftwrk.caNovember 18, 2016
ACG 2016. P394. 5-ASA and Chemoprevention in Inflammatory Bowel Disease: A Population-Based Analysis Alastair Dorreen,…
jwood@krftwrk.caNovember 18, 2016
